Rhythm Pharmaceuticals Inc (NASDAQ:RYTM): Samuel Isaly’s OrbiMed Advisors filed an amended 13D.
You can check out OrbiMed Advisors’ latest holdings and filings here.
Please follow OrbiMed Advisors (if you aren’t already doing so) to get real-time email alerts whenever we publish an article about OrbiMed Advisors or update its stock holdings.
Follow Sam Isaly's OrbiMed Advisors
You can access the original SEC filing by clicking here.
Ownership Summary Table
Name | Sole Voting Power | Shared Voting Power | Sole Dispositive Power | Shared Dispositive Power | Aggregate Amount Owned Power | Percent of Class |
---|---|---|---|---|---|---|
OrbiMed Advisors | 0 | 2,901,295 | 0 | 2,901,295 | 2,901,295 | 10.7 % |
OrbiMed Capital GP V | 0 | 2,901,295 | 0 | 2,901,295 | 2,901,295 | 10.7 % |
Samuel D. Isaly | 0 | 2,901,295 | 0 | 2,901,295 | 2,901,295 | 10.7 % |
Follow Sam Isaly's OrbiMed Advisors
Page 1 of 14 – SEC Filing
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13D
RHYTHM PHARMACEUTICALS, INC.
COMMON STOCK
76243J105
OrbiMed Advisors LLC
OrbiMed Capital GP V LLC
Samuel D. Isaly
601 Lexington Avenue, 54th Floor
New York, NY 10022
Telephone: (212) 739-6400
Authorized to Receive Notices and Communications)
October 10, 2017
Follow Rhythm Pharmaceuticals Inc. (NASDAQ:RYTM)
Follow Rhythm Pharmaceuticals Inc. (NASDAQ:RYTM)
Page 2 of 14 – SEC Filing
CUSIP No. 76243J105 | ||||
1 | NAME OF REPORTING PERSON OrbiMed Advisors LLC | |||
2 | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP | (a) ☐ (b) ☐ | ||
3 | SEC USE ONLY | |||
4 | SOURCE OF FUNDS AF | |||
5 | CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e) | ☐ | ||
6 | CITIZENSHIP OR PLACE OF ORGANIZATION Delaware | |||
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH | 7 | SOLE VOTING POWER 0 | ||
8 | SHARED VOTING POWER 2,901,295 | |||
9 | SOLE DISPOSITIVE POWER 0 | |||
10 | SHARED DISPOSITIVE POWER 2,901,295 | |||
11 | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 2,901,295 | |||
12 | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (See Instructions) | ☐ | ||
13 | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 10.7% (1) | |||
14 | TYPE OF REPORTING PERSON (See Instructions) IA |
(1) | This percentage is calculated based upon 27,131,484 outstanding shares of common stock, par value $0.001 per share (the “Shares”), of Rhythm Pharmaceuticals, Inc. (the “Issuer”), as set forth in the Issuer’s Form 424B4, filed with the Securities and Exchange Commission on October 5, 2017. |
Follow Rhythm Pharmaceuticals Inc. (NASDAQ:RYTM)
Follow Rhythm Pharmaceuticals Inc. (NASDAQ:RYTM)
Page 3 of 14 – SEC Filing
CUSIP No. 76243J105 | ||||
1 | NAME OF REPORTING PERSON OrbiMed Capital GP V LLC | |||
2 | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP | (a) ☐ (b) ☐ | ||
3 | SEC USE ONLY | |||
4 | SOURCE OF FUNDS AF | |||
5 | CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e) | ☐ | ||
6 | CITIZENSHIP OR PLACE OF ORGANIZATION Delaware | |||
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH | 7 | SOLE VOTING POWER 0 | ||
8 | SHARED VOTING POWER 2,901,295 | |||
9 | SOLE DISPOSITIVE POWER 0 | |||
10 | SHARED DISPOSITIVE POWER 2,901,295 | |||
11 | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 2,901,295 | |||
12 | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (See Instructions) | ☐ | ||
13 | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 10.7% (1) | |||
14 | TYPE OF REPORTING PERSON (See Instructions) OO |
(1) | This percentage is calculated based upon 27,131,484 outstanding shares of common stock, par value $0.001 per share (the “Shares”), of Rhythm Pharmaceuticals, Inc. (the “Issuer”), as set forth in the Issuer’s Form 424B4, filed with the Securities and Exchange Commission on October 5, 2017. |
Follow Rhythm Pharmaceuticals Inc. (NASDAQ:RYTM)
Follow Rhythm Pharmaceuticals Inc. (NASDAQ:RYTM)
Page 4 of 14 – SEC Filing
CUSIP No. 76243J105 | ||||
1 | NAME OF REPORTING PERSON Samuel D. Isaly | |||
2 | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP | (a) ☐ (b) ☐ | ||
3 | SEC USE ONLY | |||
4 | SOURCE OF FUNDS AF | |||
5 | CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e) | ☐ | ||
6 | CITIZENSHIP OR PLACE OF ORGANIZATION Delaware | |||
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH | 7 | SOLE VOTING POWER 0 | ||
8 | SHARED VOTING POWER 2,901,295 | |||
9 | SOLE DISPOSITIVE POWER 0 | |||
10 | SHARED DISPOSITIVE POWER 2,901,295 | |||
11 | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 2,901,295 | |||
12 | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (See Instructions) | ☐ | ||
13 | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 10.7% (1) | |||
14 | TYPE OF REPORTING PERSON (See Instructions) IN |
(1) | This percentage is calculated based upon 27,131,484 outstanding shares of common stock, par value $0.001 per share (the “Shares”), of Rhythm Pharmaceuticals, Inc. (the “Issuer”), as set forth in the Issuer’s Form 424B4, filed with the Securities and Exchange Commission on October 5, 2017. |
Follow Rhythm Pharmaceuticals Inc. (NASDAQ:RYTM)
Follow Rhythm Pharmaceuticals Inc. (NASDAQ:RYTM)
Page 5 of 14 – SEC Filing
Item 1. | Security and Issuer |
Item 2. | Identity and Background |
(i) | name; |
(ii) | business address; |
(iii) | present principal occupation or employment and the name, principal business and address of any corporation or other organization in which such employment is conducted; |
(iv) | citizenship. |
Item 3. | Source and Amount of Funds or Other Consideration |
Follow Rhythm Pharmaceuticals Inc. (NASDAQ:RYTM)
Follow Rhythm Pharmaceuticals Inc. (NASDAQ:RYTM)
Page 6 of 14 – SEC Filing
Item 4. | Purpose of Transaction |
Follow Rhythm Pharmaceuticals Inc. (NASDAQ:RYTM)
Follow Rhythm Pharmaceuticals Inc. (NASDAQ:RYTM)
Page 7 of 14 – SEC Filing
Item 5. | Interest in Securities of the Issuer |
Follow Rhythm Pharmaceuticals Inc. (NASDAQ:RYTM)
Follow Rhythm Pharmaceuticals Inc. (NASDAQ:RYTM)
Page 8 of 14 – SEC Filing
Item 6. | Contracts, Arrangements, Understandings or Relationship with Respect to Securities of the Issuer |
Follow Rhythm Pharmaceuticals Inc. (NASDAQ:RYTM)
Follow Rhythm Pharmaceuticals Inc. (NASDAQ:RYTM)
Page 9 of 14 – SEC Filing
Follow Rhythm Pharmaceuticals Inc. (NASDAQ:RYTM)
Follow Rhythm Pharmaceuticals Inc. (NASDAQ:RYTM)
Page 10 of 14 – SEC Filing
Item 7. | Materials to Be Filed as Exhibits |
Exhibit | Description |
1. | Joint Filing Agreement among OrbiMed Advisors LLC, OrbiMed Capital GP V LLC and Samuel D. Isaly. |
2. | Lock-Up Agreement. |
3. | Amended and Restated Investors’ Rights Agreement by and among the Issuer and each of the persons listed on Schedule A thereto, dated as of August 21, 2017 (incorporated by reference to Exhibit 4.2 to the Issuer’s Registration Statement on Form S-1 (SEC 333-220337), filed with the SEC on September 5, 2017). |
Follow Rhythm Pharmaceuticals Inc. (NASDAQ:RYTM)
Follow Rhythm Pharmaceuticals Inc. (NASDAQ:RYTM)
Page 11 of 14 – SEC Filing
OrbiMed Advisors LLC | ||||
By: | /s/ Samuel D. Isaly | |||
Name: | Samuel D. Isaly | |||
Title: | Managing Member | |||
OrbiMed Capital GP V LLC | ||||
By: | OrbiMed Advisors LLC | |||
By: | /s/ Samuel D. Isaly | |||
Name: | Samuel D. Isaly | |||
Title: | Managing Member | |||
Samuel D. Isaly | ||||
/s/ Samuel D. Isaly | ||||
Name: | Samuel D. Isaly |
Follow Rhythm Pharmaceuticals Inc. (NASDAQ:RYTM)
Follow Rhythm Pharmaceuticals Inc. (NASDAQ:RYTM)
Page 12 of 14 – SEC Filing
Name | Position with Reporting Person | Principal Occupation |
Samuel D. Isaly | Managing Member | Managing Member OrbiMed Advisors LLC |
Carl L. Gordon | Member | Member OrbiMed Advisors LLC |
Sven H. Borho German and Swedish Citizen | Member | Member OrbiMed Advisors LLC |
Jonathan T. Silverstein | Member | Member OrbiMed Advisors LLC |
W. Carter Neild | Member | Member OrbiMed Advisors LLC |
Geoffrey C. Hsu | Member | Member OrbiMed Advisors LLC |
Evan D. Sotiriou | Chief Financial Officer | Chief Financial Officer OrbiMed Advisors LLC |
Follow Rhythm Pharmaceuticals Inc. (NASDAQ:RYTM)
Follow Rhythm Pharmaceuticals Inc. (NASDAQ:RYTM)
Page 13 of 14 – SEC Filing
Follow Rhythm Pharmaceuticals Inc. (NASDAQ:RYTM)
Follow Rhythm Pharmaceuticals Inc. (NASDAQ:RYTM)
Page 14 of 14 – SEC Filing
Exhibit | Description |
1. | Joint Filing Agreement among OrbiMed Advisors LLC, OrbiMed Capital GP V LLC and Samuel D. Isaly. |
2. | Lock-Up Agreement. |
3. | Amended and Restated Investors’ Rights Agreement by and among the Issuer and each of the persons listed on Schedule A thereto, dated as of August 21, 2017 (incorporated by reference to Exhibit 4.2 to the Issuer’s Registration Statement on Form S-1 (SEC 333-220337), filed with the SEC on September 5, 2017). |